CLINICAL TRIALS PROFILE FOR DATSCAN

All Clinical Trials for DATSCAN

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00129181 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	Completed	GE Healthcare	N/A	2005-01-01	This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00129181 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	Completed	Pfizer	N/A	2005-01-01	This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00129181 ↗	Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease	Completed	Institute for Neurodegenerative Disorders	N/A	2005-01-01	This study investigates whether there is a change in 123iodine-2ß- carbomethoxy-3ß-(4-iodophenyl) tropane ([123I]ß-CIT) uptake after short-term treatment with levodopa compared to either dopamine agonist or placebo.
NCT00209456 ↗	Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia	Completed	GE Healthcare	Phase 3	2003-11-01	The study is designed to determine the diagnostic efficacy of the visual assessment of SPECT scans in differentiating between probable dementia with Lewy Bodies (DLB) and non-DLB dementia subjects determined by the clinical diagnosis of an independent expert consensus panel used as the standard of truth.
NCT01141023 ↗	Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression	Active, not recruiting	Institute for Neurodegenerative Disorders	Phase 2	2010-06-01	This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.
NCT01141023 ↗	Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression	Active, not recruiting	Ken Marek, MD	Phase 2	2010-06-01	This is a observational, multi-center study to assess progression of clinical features, imaging and biologic biomarkers in Parkinson disease (PD) patients compared to healthy controls (HC) and in PD patient subtypes. The primary objective of this study is to identify clinical, imaging and biologic markers of PD progression for use in clinical trials of disease-modifying therapies.

Clinical Trial Conditions for DATSCAN

Condition Name

Condition Name for DATSCAN
Intervention	Trials
Parkinson Disease	4
Parkinsonian Syndrome	2
REM Sleep Behavior Disorder	2
Healthy Subjects (HS)	1

Condition MeSH

Condition MeSH for DATSCAN
Intervention	Trials
Parkinson Disease	8
Parkinsonian Disorders	4
Lewy Body Disease	3
Dementia	3

Clinical Trial Locations for DATSCAN

Trials by Country

Trials by Country for DATSCAN
Location	Trials
United States	24
China	7
Germany	3
Norway	2
Austria	2

Trials by US State

Trials by US State for DATSCAN
Location	Trials
Florida	3
Connecticut	3
Minnesota	2
California	2
Arizona	2

Clinical Trial Progress for DATSCAN

Clinical Trial Phase

Clinical Trial Phase for DATSCAN
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	4
Phase 2	6

Clinical Trial Status

Clinical Trial Status for DATSCAN
Clinical Trial Phase	Trials
Completed	7
Enrolling by invitation	3
Recruiting	3

Clinical Trial Sponsors for DATSCAN

Sponsor Name

Sponsor Name for DATSCAN
Sponsor	Trials
GE Healthcare	5
PPD	2
Institute for Neurodegenerative Disorders	2

Sponsor Type

Sponsor Type for DATSCAN
Sponsor	Trials
Other	24
Industry	10